← Back to Search

SPECT CT for Prostate Cancer

Phase 1

Waitlist Available

Led By Lilja Solnes, MD

Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is testing how well SPECT CT works as a diagnostic tool. It is open label, which means that participants and researchers know which treatment is being given, and it is not randomized, meaning that participants are not assigned by chance to a particular group.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Accuracy for Prediction of Progression Free Survival as determined by Quantitative bone SPECT indices (QBSIs)

Secondary outcome measures

Ability of QBSPECT to detect recurrence of metastatic disease as determined by QBSI in 60 patients.

Accuracy of NaF PET/CT as determined by difference in QBSI from SPECT versus QBSI from NaF PET/CT in 20 patients

Accuracy of PSMA PET/CT as determined by difference in QBSI from SPECT versus QBSI from PSMA PET/CT in 20 patients

+2 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: "Cohort C" - SPECT CT and WB-MRIExperimental Treatment2 Interventions

Intervention 1: SPECT CT Intervention 2: WB-MRI

Group II: "Cohort B" - SPECT CT and 18F-DCFPyL PET/CTExperimental Treatment2 Interventions

Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT

Group III: "Cohort A" - SPECT CT and NaF PETExperimental Treatment2 Interventions

Intervention 1: SPECT CT Intervention 2: NaF PET

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

18F-DCFPyL PET/CT

2017

Completed Phase 2

~120

SPECT CT

2020

N/A

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,664 Total Patients Enrolled

560 Trials studying Prostate Cancer

507,170 Patients Enrolled for Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor

557 Previous Clinical Trials

32,897 Total Patients Enrolled

56 Trials studying Prostate Cancer

3,345 Patients Enrolled for Prostate Cancer

Lilja Solnes, MDPrincipal InvestigatorJohns Hopkins University

1 Previous Clinical Trials

74 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has there been any additional research conducted in regards to SPECT CT?

"Currently, 18 clinical trials concerning SPECT CT are underway with none of them in the third phase. Of these studies, 27 locations offer participation; Baltimore, Maryland is one such site."

Answered by AI

How many individuals have enlisted in this investigation thus far?

"Affirmative. Clinicaltrials.gov describes the study as being actively recruiting, having been originally posted on November 15th 2019 and most recently updated on December 14th 2021. This research project is trying to enrol 60 patients from a single medical centre."

Answered by AI

What type of conditions is SPECT CT frequently employed to manage?

"SPECT CT is a diagnostic imaging technique that utilizes positron emission tomography to detect and monitor prostate cancer."

Answered by AI

Has the SPECT CT technology obtained authorization from the FDA?

"The safety of SPECT CT has been assessed as a 1 due to the preliminary nature of this Phase 1 trial, with limited data in regards to efficacy and security."

Answered by AI

Are there any vacancies for individuals interested in participating in this investigation?

"The clinical trial is still open for recruitment, with its first posting dated November 15th 2019 and last edit on December 14th 2021 according to the records of clinicaltrials.gov."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

2019. "Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03619655.